Efficacy and safety of daratumumab in the treatment of relapsed ...

Role of daratumumab in relapsed or refractory multiple myeloma ...

Despite the advancement in MM treatment, the management of RRMM still poses a challenge.[12] Thus, the efficacy and safety of novel therapeutics need to be ...

Paper: Daratumumab with Dexamethasone in Patients ... - Abstract

The median time from the first dose of study treatment until the first response (≥PR) was 0.9 months. RRR was 17.1%. By the cut-off date, 37.1% ...

Clinical Trials Using Daratumumab - NCI

But selinexor is not used until myeloma comes back (relapses) after initial treatment. Giving selinexor in the initial treatment may be a superior type of ...

Treatment patterns and effectiveness of patients with multiple ...

Daratumumab monotherapy was first approved by the Food and Drug Administration (FDA) for patients with relapsed and/or refractory MM who have ...

results from a randomised, multicentre, open-label, phase 3 study

Carfilzomib in combination with daratumumab has shown substantial efficacy with tolerable safety in relapsed or refractory multiple myeloma in a phase 1 study.

SA58 Real-World Outcomes for the Treatment of Relapsed ...

These findings confirm and provide certainty that in a real-world setting, daratumumab is effective across different patient populations with RRMM regardless of ...

Real-world Duration of Use and Dosing Frequency of Daratumumab ...

... therapy for relapsed or refractory MM cases. We assessed the ... ∙ Chai, Y. Efficacy and safety of daratumumab in the treatment of ...

Daratumumab Salvage Therapy Effective in Relapsed Myeloma ...

Daratumumab salvage therapy demonstrated a 1-year overall survival rate of 90.9% in patients with multiple myeloma who relapsed following ...

Trials for DARZALEX FASPRO

View clinical trial information for DARZALEX FASPRO® relapsed or refractory patients, including study design, efficacy, and safety.

Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders

In 2020, subcutaneous (SC) daratumumab was approved for the treatment of multiple myeloma, and randomized data suggest a lower rate of IRRs compared with IV ...

Daratumumab monotherapy in relapsed and refractory multiple ...

Real-world experience with daratumumab monotherapy has continuously been reported since its approval as a treatment for RRMM [10-13]. The ...

RESULTS ON EFFICACY AND SAFETY OF DARATUMUMAB WITH ...

For patients with relapsed/refractory MM (RRMM) there is a need for effective therapies with low or minimal risk of renal toxicity. Daratumumab ...

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple ...

A response occurred in 71% of the patients in the ide-cel group and in 42% of those in the standard-regimen group (P<0.001); a complete response ...

DARZALEX® (daratumumab)-based maintenance regimens show ...

Minimal residual disease (MRD)-negativity rate of 10-5 more than doubled by 12 months with DARZALEX FASPRO® in maintenance therapy compared ...

Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients

DARA is widely used in combination with other agents, not only in newly diagnosed cases, but also in relapsed/refractory cases [9,49,50,51]. Its high ...

Elranatamab in Combination with Daratumumab for Patients with ...

... assess the efficacy and safety of elranatamab monotherapy or in combination with daratumumab in relapsed refractory multiple myeloma patients.

DREAMM-7 phase III trial shows Blenrep combination nearly tripled ...

... daratumumab plus BorDex in second-line and later treatment of relapsed or refractory multiple myeloma. These data will be presented at the ...

Full article: Pomalidomide, dexamethasone, and daratumumab ...

Patients with relapsed/refractory multiple myeloma (RRMM) need proven subsequent therapies after early-line lenalidomide treatment failure. The phase 2 MM-014 ...

Antibody–drug conjugate, GSK2857916, in relapsed/refractory ...

Of the 21 patients without prior daratumumab treatment, 15 achieved a confirmed overall response (71.4%; 95% CI 47.8–88.7); of the 13 patients ...

Daratumumab-Based Treatment for Immunoglobulin Light-Chain ...

In patients with relapsed or refractory AL amyloidosis, daratumumab has shown promising efficacy in terms of hematologic responses and ...